复合EGFR突变以PACC为主且对二代TKI敏感性增强
研究分析15851例EGFR突变NSCLC游离DNA样本,发现PACC突变占9%且66.2%为顺式复合突变,而经典突变和20外显子插入多为单突变。体外及1542例真实世界数据表明,复合PACC突变与单PACC突变药物敏感性相似,对二代TKI敏感性优于一代或三代TKI。
要点
- PACC突变占EGFR突变样本9%,其中66.2%为顺式复合突变。
- 复合PACC突变对二代TKI敏感性优于一代或三代TKI。
- 真实世界数据支持PACC突变患者二代TKI疗效更优。
核心结论
- EGFR PACC突变主要以顺式复合突变形式出现。
- 复合PACC突变与单PACC突变药物敏感性模式相似。
- 携带单或复合PACC突变的NSCLC患者接受二代TKI疗效优于一代或三代TKI。
研究设计与样本
- 研究基于15851例EGFR突变NSCLC游离DNA样本分析突变景观。
- 采用体外Ba/F3模型评估药物敏感性。
- 回顾性分析MD Anderson癌症中心真实世界队列、Guardant Health真实世界队列及文献综述,共1542例患者。
主要发现
- PACC突变占所有EGFR突变的9%(1421/15851),其中66.2%(941/1421)为顺式复合突变。
- 经典突变中84.3%(9576/11365)和20外显子插入中88.6%(848/957)主要为单突变(p<0.0001)。
- 体外实验显示复合PACC突变(包括PACC+PACC和PACC+经典突变)对二代TKI敏感性优于一代或三代TKI。
- 回顾性数据支持单或复合PACC突变患者接受二代TKI结局优于一代或三代TKI。
临床怎么用
- 对EGFR突变NSCLC进行游离DNA检测时,应识别PACC复合突变。
- 携带PACC单或复合突变的患者,优先考虑二代TKI治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: EGFR kinase domain mutations in NSCLC can be classified into four subgroups (classical-like, exon 20 loop insertions, P-loop and αC-helix compressing [PACC], and T790M-like) to effectively predict the response to tyrosine kinase inhibitors (TKIs). These mutations can occur individually or as compound mutations. The frequency, drug sensitivity, and clinical outcomes of compound EGFR mutations, particularly those involving PACC and classical co-mutations, remain incompletely defined. METHODS: We characterized the landscape of single and compound EGFR mutations in 15,851 EGFR-mutant NSCLC samples tested by cell-free DNA. Drug sensitivity was assessed using in vitro Ba/F3 models. Clinical outcomes were retrospectively evaluated from the MD Anderson Cancer Center real-world cohort, the Guardant Health real-world cohort, and a literature review, totaling 1542 patients. RESULTS: Among all EGFR mutations, PACC mutations were found in 9% (1421/15,851) of samples and occurred predominantly as in cis compound mutations (66.2%, 941/1421). Conversely, 84.3% (9576/11,365) of classical mutations and 88.6% (848/957) of exon 20 insertions were mainly single mutations, respectively (p < 0.0001). In vitro testing revealed that compound PACC mutations, including PACC plus PACC and PACC plus classical mutations, exhibited sensitivity profiles similar to those of single PACC mutations, with enhanced sensitivity to second- versus first- or third-generation TKIs. Analysis of retrospective data supported the finding that patients with NSCLC harboring single or compound PACC mutations had improved outcomes with second-generation TKIs compared with first- or third-generation TKIs. CONCLUSION: EGFR PACC mutations primarily occur as in cis compound mutations. Compound PACC mutations exhibit similar patterns of drug sensitivity to those of single PACC mutations.
引用
- Liu X, Stamboulian M, Borgeaud M, et al. Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors. J Thorac Oncol. 2026. PMID: 42191070. doi:10.1016/j.jtho.2026.103948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。